eye drops
Sponsors
Seagen Inc., Oculis Operations S.a.r.l., Medical Center - University Of Freiburg, Inmunotek S.L., Chang Gung Memorial Hospital
Conditions
Atropine AllergyCataractDiabetic Macular Edema (DME)Dry EyeGrass pollen induced allergic rhinitis or rhinoconjunctivitisMyopia, ProgressiveProgressive myopiaSecond- or Third-Line Recurrent or Metastatic Cervical Cancer
Phase 2
A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
CompletedCTIS2023-507208-30-00
Start: 2022-09-20End: 2024-07-29Target: 49Updated: 2024-04-12
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.
Not yet recruitingCTIS2025-524580-21-00
Target: 450Updated: 2026-05-29
Phase 3
C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
CompletedCTIS2023-503813-31-01
Start: 2021-09-17End: 2025-11-18Target: 188Updated: 2025-11-19
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
CompletedCTIS2023-507207-66-00
End: 2024-07-29Target: 133Updated: 2024-05-24
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2024-515717-17-00
Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07
Low-dose AtropIne for Myopia control in children
Active, not recruitingCTIS2024-513091-17-00
Start: 2021-09-29Target: 300Updated: 2024-10-24